Eli Lilly & Incyte v. MSN Labs: Olumiant Baricitinib ANDA Patent Dispute
Eli Lilly and Incyte brought a Paragraph IV ANDA infringement action against MSN Laboratories and MSN Pharmaceuticals over US8158616, the core patent covering Olumiant® (baricitinib) 4 mg tablets. Filed in Delaware in November 2023, the case was consolidated within 191 days into a broader coordinated ANDA proceeding involving multiple generic challengers.
Baricitinib ANDA battle folded into Delaware’s multi-defendant patent war
On November 8, 2023, Eli Lilly and Company, Incyte Holdings Corporation, and Incyte Corporation filed suit in the District of Delaware against MSN Laboratories Private Limited and MSN Pharmaceuticals Inc. The action arose from MSN’s ANDA No. 217585, filed with the FDA seeking approval of a generic version of Olumiant® (baricitinib) tablets prior to expiration of US Patent No. 8,158,616 — the foundational compound patent covering this JAK1/JAK2 inhibitor approved for rheumatoid arthritis and other inflammatory indications.
The case closed on May 17, 2024, not through a merits ruling but via court-approved consolidation into C.A. No. 22-1114 (CFC), an already-active coordinated proceeding involving multiple ANDA filers challenging the same ‘616 patent. Under the stipulation, MSN’s deadline to respond to the complaint was extended to February 12, 2024, and all future filings, including trial, are governed by the scheduling order of the lead consolidated case. This is a procedural outcome — no infringement finding, no invalidity ruling.
The 191-day consolidation timeline is consistent with efficient docket management in multi-wave ANDA litigation, where courts and parties typically seek to align discovery and trial schedules across all generic challengers. The consolidation suggests the plaintiffs and MSN agreed that litigating separately would duplicate effort and resources. The substantive question — whether MSN’s generic baricitinib product infringes the ‘616 patent — remains live and will be resolved within the consolidated C.A. No. 22-1114 proceeding.
Filing to Case Consolidated in 191 days
191 days from filing to consolidation — rapid procedural resolution into coordinated ANDA litigation
Case consolidated: what the procedural merger means for both parties
Consolidation is not a dismissal — the dispute continues
Case consolidation under FRCP Rule 42 merges related actions for efficiency. Here, C.A. No. 23-1277 was folded into the lead ANDA docket C.A. No. 22-1114. MSN’s claims and defences are fully preserved — no rights are waived and no merits have been decided. All filings now occur under the lead case number, streamlining discovery across multiple generic defendants challenging the same patent.
Procedural merger — merits intactLilly and Incyte gain coordinated enforcement efficiency
By consolidating MSN into the existing multi-defendant proceeding, Eli Lilly and Incyte avoid duplicative depositions, expert proceedings, and trial preparation. The ‘616 patent remains asserted and enforceable. A single trial outcome on validity and infringement will bind all consolidated defendants, including MSN — maximising Lilly’s leverage from a single adjudication.
Coordinated enforcement strategyMSN’s challenge advances within a crowded multi-defendant docket
MSN Laboratories joins other ANDA filers in the consolidated proceeding, which may provide strategic benefits: shared invalidity arguments, coordinated prior art discovery, and the potential to free-ride on favourable rulings obtained by co-defendants. However, MSN also inherits the consolidated scheduling order, reducing its ability to independently control litigation pace or settlement timing.
Shared invalidity strategy possibleBaricitinib market entry timeline hinges on the consolidated outcome
Olumiant® generated significant revenue for Lilly and Incyte in the rheumatoid arthritis and JAK inhibitor market. The consolidated litigation’s outcome will determine whether MSN — and other ANDA filers — can launch a generic baricitinib product. A finding of validity and infringement would extend Lilly’s market exclusivity; invalidity or non-infringement would accelerate generic entry and reshape the JAK inhibitor competitive landscape.
Generic entry timeline unresolvedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Eli Lilly & Company | Company | Pharmaceutical co-plaintiffs — co-holders and licensees of US8158616 covering baricitinibSearch in Eureka ↗ |
| Co-Plaintiff | Incyte Holdings Corporation | Company | Search in Eureka ↗ |
| Co-Plaintiff | Incyte Corporation | Company | Search in Eureka ↗ |
| Defendant | MSN Laboratories Private Limited | Individual | Indian generic pharmaceutical manufacturer and its US affiliate seeking FDA approval for generic baricitinibSearch in Eureka ↗ |
| Co-Defendant | MSN Pharmaceuticals, Inc. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Jack B. Blumenfeld | Attorney | Counsel for Eli Lilly & CompanySearch in Eureka ↗ |
| Plaintiff counsel | Jeremy A. Tigan | Attorney | Counsel for Eli Lilly & CompanySearch in Eureka ↗ |
| Plaintiff law firm | Morris, Nichols, Arsht & Tunnell LLP | Law Firm | Representing Eli Lilly & CompanySearch in Eureka ↗ |
| Presiding judge | Judge Jennifer L. Hall | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The stipulated order consolidating C.A. No. 23-1277 into C.A. No. 22-1114 is a purely procedural disposition — it resolves no question of infringement, validity, or enforceability of US8158616. The verdict text confirms the parties mutually agreed to consolidate to streamline discovery and conserve resources. No merits finding was made against either party. The substantive patent dispute over baricitinib remains live and will be adjudicated in the lead consolidated docket before Judge Connolly in Delaware.
US8158616B2 — Baricitinib compound patent covering Olumiant® tablets
US Patent No. 8,158,616 (application No. 12/401,348) covers baricitinib, a selective JAK1 and JAK2 inhibitor developed for the treatment of moderate-to-severe rheumatoid arthritis and marketed as Olumiant® by Eli Lilly and Incyte. As a compound patent, it protects the active molecule itself — the broadest and most commercially significant category of pharmaceutical patent protection under the Hatch-Waxman framework. The patent’s expiration date is the critical trigger for permissible generic ANDA filing.
The ‘616 patent is strategically central because a compound claim cannot be designed around — any generic formulation of baricitinib must confront it directly through invalidity or non-infringement arguments. Lilly and Incyte’s coordinated enforcement against multiple ANDA filers in consolidated Delaware proceedings reflects the high commercial stakes: Olumiant® competes in a crowded JAK inhibitor market alongside tofacitinib and upadacitinib, making baricitinib’s exclusivity period a significant revenue variable. Competitors and follow-on innovators should monitor the consolidated proceeding for claim construction rulings that may define the patent’s effective scope.
Should you run an FTO analysis against US8158616B2?
Any company developing a JAK inhibitor therapeutic — whether a baricitinib generic, a next-generation JAK1/JAK2 selective compound, or a reformulation for a new indication — should assess freedom to operate against US8158616. The compound claim’s scope, as it will be construed in the consolidated Delaware proceeding, directly determines whether novel small-molecule candidates infringe. R&D teams working on JAK pathway drugs should not assume structural differentiation from baricitinib is sufficient without claim-level analysis.
PatSnap Eureka’s FTO Search Agent can map the full claim landscape of US8158616, identify prosecution history estoppel limitations, surface prior art cited during examination, and flag related family members in ex-US jurisdictions. For companies watching the consolidated C.A. No. 22-1114 litigation, Eureka can also monitor for claim construction orders and trial outcomes that may narrow or expand the patent’s effective scope — allowing R&D and IP teams to make launch and development decisions in real time.
Run a freedom-to-operate analysis on US8158616B2 to assess your product’s exposure
Run FTO in Eureka →Similar ANDA patent cases involving JAK inhibitor compounds in Delaware
Explore related Hatch-Waxman ANDA litigation over JAK inhibitor patents in the District of Delaware, including multi-defendant consolidated proceedings.
What this case signals for the JAK inhibitor ANDA IP landscape
Multi-wave ANDA consolidations in Delaware are a defining feature of biologics-adjacent small-molecule patent enforcement. This case illustrates the pattern.
Consolidation is a plaintiffs’ tool — and a signal of patent strength
When patent holders consolidate multiple ANDA filers into a single proceeding, it typically signals confidence in the patent’s validity. A single favourable ruling binds all defendants. Generic companies should assess whether their invalidity arguments are sufficiently differentiated to survive a consolidated trial, or whether coordination with co-defendants is the more pragmatic route.
The ‘616 patent is the central battleground for baricitinib exclusivity
US8158616 is the compound patent covering baricitinib itself — the hardest category of patent to design around in small-molecule ANDA litigation. Any generic entrant must either invalidate it or demonstrate non-infringement of the compound claim. Companies monitoring the consolidated C.A. No. 22-1114 docket should track claim construction rulings closely, as they will define the scope of the exclusivity period.
Eli v MSN — key questions answered
The case was closed on May 17, 2024 via consolidation into C.A. No. 22-1114 (CFC), a coordinated multi-defendant ANDA proceeding in Delaware. No merits ruling on infringement or validity of US8158616 was issued in this docket. The dispute over baricitinib (Olumiant®) continues in the lead consolidated case.
The asserted patent is US Patent No. 8,158,616 (application 12/401,348), a compound patent covering baricitinib — the active JAK1/JAK2 inhibitor in Olumiant® tablets. It is co-owned or licensed between Eli Lilly and Incyte and represents the foundational exclusivity barrier for generic baricitinib ANDA filers.
ANDA No. 217585 is MSN Laboratories’ Abbreviated New Drug Application submitted to the FDA seeking approval of a generic version of Olumiant® (baricitinib) tablets prior to expiration of US8158616. Filing an ANDA with a Paragraph IV certification triggers Hatch-Waxman patent litigation, which Lilly and Incyte commenced with this action.
Consolidation means MSN’s case is now litigated under the lead docket C.A. No. 22-1114 alongside other generic challengers. MSN’s invalidity and non-infringement arguments are fully preserved, but the scheduling order, discovery, and trial proceedings are shared across all consolidated defendants. The merits of MSN’s ANDA challenge remain unresolved.
The plaintiffs are Eli Lilly and Company, Incyte Holdings Corporation, and Incyte Corporation. Eli Lilly markets Olumiant® and Incyte is a co-development and commercialisation partner. Together they hold or licence the rights to enforce US8158616 against generic filers under the Hatch-Waxman framework.
PatSnap Eureka searches patents and litigation data to answer instantly.